This approach is based on the findings of recent clinical trials with SGLT2i and GLP-1 RA, which have demonstrated clinically relevant benefits in a broad group of T2DM patients with varying eGFR levels and different rates of albuminuria, as long as they have CKD. The gene discussed is GLP1R; the disease is chronic kidney disease.